TipRanks
Advertisement
Advertisement

ESALF Stock Latest News

Eisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results
Company AnnouncementsEisai’s Lenvima Combo Trial in Liver Cancer Ends With Mixed but Market-Relevant Results
13d ago
ESALF
Eisai’s E2086 Metabolism Study Clears a Key Early Milestone for Investors
PremiumCompany Announcements
Eisai’s E2086 Metabolism Study Clears a Key Early Milestone for Investors
26d ago
ESALF
Lenvatinib Combo Falls Short in Esophageal Cancer: What Eisai Investors Need to Know
PremiumCompany Announcements
Lenvatinib Combo Falls Short in Esophageal Cancer: What Eisai Investors Need to Know
26d ago
ESALF
Eisai’s E2086 Drug-Interaction Study Sets Up Long-Term Pipeline Potential
PremiumCompany Announcements
Eisai’s E2086 Drug-Interaction Study Sets Up Long-Term Pipeline Potential
1M ago
ESALF
Eisai’s New LEQEMBI Registry: Real World Safety Data That Could Shape Alzheimer’s Drug Markets
PremiumCompany Announcements
Eisai’s New LEQEMBI Registry: Real World Safety Data That Could Shape Alzheimer’s Drug Markets
1M ago
ESALF
Eisai Earnings Call Highlights LEQEMBI-Driven Surge
PremiumCompany AnnouncementsEisai Earnings Call Highlights LEQEMBI-Driven Surge
2M ago
Eisai Co (ESALF) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Eisai Co (ESALF) Q1 Earnings Cheat Sheet
2M ago
Eisai’s E7090 Breast Cancer Trial Reaches Key Milestone, Setting Up Next Investor Catalyst
Premium
Company Announcements
Eisai’s E7090 Breast Cancer Trial Reaches Key Milestone, Setting Up Next Investor Catalyst
2M ago
ESALF
Eisai Earnings Call Highlights LEQEMBI-Led Growth
PremiumCompany Announcements
Eisai Earnings Call Highlights LEQEMBI-Led Growth
4M ago
Eisai’s E2086 Narcolepsy Trial Adds Quiet Upside Optionality for ESALF Investors
PremiumCompany Announcements
Eisai’s E2086 Narcolepsy Trial Adds Quiet Upside Optionality for ESALF Investors
4M ago
ESALF
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Eisai Co (ESALF) Q4 Earnings Cheat Sheet
4M ago
Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
PremiumCompany Announcements
Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
5M ago
ESALF
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsEisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
5M ago
ESALF
Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
Premium
Company Announcements
Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
7M ago
ESALF
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
Premium
Company Announcements
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
7M ago
ESALF
ESALF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESALF Earnings this Week: How Will it Perform?
7M ago
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
PremiumCompany Announcements
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
11M ago
ESALF
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
PremiumCompany Announcements
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
11M ago
ESALF
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
11M ago
ESALF
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
PremiumCompany AnnouncementsEisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
11M ago
ESALF
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
Premium
Company Announcements
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
11M ago
ESALF
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
Premium
Company Announcements
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
11M ago
ESALF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >